Literature DB >> 10146864

The formulary decision-making process in a health maintenance organisation setting.

M D Shepherd1, R D Salzman.   

Abstract

The goal of a health maintenance organisation (HMO) is to provide high quality, cost-effective healthcare services and products which meet the needs of the membership. Providing and managing pharmaceutical products and services within the HMO is a major aspect of accomplishing this goal. Several decisions must be made in developing, implementing and maintaining a formulary system. The numbers of people seeking their healthcare from HMOs in the US has increased 4-fold in 10 years, and several model types of HMOs have developed, including network HMOs, group HMOs, independent practitioner associations and staff models. HMOs utilising formulary systems provided cover to 76% of enrollees in 1992. Formulary system management and decision making entails the use of open vs closed formularies and the role of the pharmacy and therapeutics (P & T) committee. Product selection takes into account efficacy, safety, costs, patient acceptance, ease of use, dosage forms, preparation requirements, stability and storage requirements and the reputation of the manufacturer and the service it provides. We list and describe various policy decisions which HMO pharmaceutical decision makers must address if the formulary system is to become an efficient tool for the HMO.

Entities:  

Mesh:

Year:  1994        PMID: 10146864     DOI: 10.2165/00019053-199405010-00005

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  14 in total

1.  Application of decision analysis to drug selection for formulary addition.

Authors:  J J Kresel; H C Hutchings; D N MacKay; M C Weinstein; J L Read; K Taylor-Halvorsen; H Ashley
Journal:  Hosp Formul       Date:  1987-07

2.  Mission, role, and functions of the P & T Committee.

Authors:  J E Bell; P J Evans; R C Standish
Journal:  Hosp Formul       Date:  1983-06

3.  Drug formularies: myths-in-formation.

Authors:  T D Rucker; G Schiff
Journal:  Med Care       Date:  1990-10       Impact factor: 2.983

Review 4.  Managed care in the United States: promises, evidence to date and future directions.

Authors:  J P Hadley; K Langwell
Journal:  Health Policy       Date:  1991       Impact factor: 2.980

5.  Drug product management in health maintenance organizations.

Authors:  D H Kreling; R E Mucha
Journal:  Am J Hosp Pharm       Date:  1992-02

6.  Therapeutic decision-making: a model for formulary evaluation.

Authors:  G P Sesin
Journal:  Drug Intell Clin Pharm       Date:  1986 Jul-Aug

7.  Hospital drug formularies and use of hospital services.

Authors:  F A Sloan; G S Gordon; D L Cocks
Journal:  Med Care       Date:  1993-10       Impact factor: 2.983

8.  Multiattribute evaluation in formulary decision making as applied to calcium-channel blockers.

Authors:  G E Schumacher
Journal:  Am J Hosp Pharm       Date:  1991-02

9.  Operation, formulary decision-making activities of a P & T Committee in a managed care setting.

Authors:  J Adams; J Richardson
Journal:  Hosp Formul       Date:  1991-04

10.  Implementation of an outpatient prescription drug formulary in a managed-care system.

Authors:  J Black; T Griffin; N W Beisel; M D Bartels
Journal:  Am J Hosp Pharm       Date:  1988-03
View more
  3 in total

Review 1.  The effect of managed care on prescription drug costs and benefits.

Authors:  A Lyles; F B Palumbo
Journal:  Pharmacoeconomics       Date:  1999-02       Impact factor: 4.981

Review 2.  The expanding role of pharmacy and therapeutics committees. The 1990s and beyond.

Authors:  W E Wade; W J Spruill; A T Taylor; R L Longe; D W Hawkins
Journal:  Pharmacoeconomics       Date:  1996-08       Impact factor: 4.981

Review 3.  Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 1: Depression and its treatment.

Authors:  J A Henry; C A Rivas
Journal:  Pharmacoeconomics       Date:  1997-05       Impact factor: 4.981

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.